Scholars Central

Research articlePublished 2014

CD133-positive Status Predicts Better Prognosis in Metastatic Colorectal Cancer Patients Treated with Cetuximab

Authors: Dai Inoue, Satoshi Matsusaka, Noiriko Yamamoto, Mitsukuni Suenaga, Eiji Shinozaki, Nobuyuki Mizunuma, Yuichi Ishikawa, Kiyohiko Hatake

Journal of Cytology & Histology

Volume 5 · Issue 1 · Pages 1–6

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: There are few evidence which kind of tumor is more benefit from cetuximab, more investigations of supplementary predictive factors are highly relevant. The purpose is to evaluate the prognostic significance of CD133 expression and to investigate the utility as biomarker of prognosis of metastatic colorectal cancer (mCRC) patients treated with cetuximab. Methods: We investigated progression-free survival (PFS) and overall survival (OS) of patients with mCRC about 5FU-based regimen as first line chemotherapy and cetuximab as salvage line retrospectively, and performed immunohistochemical staining to evaluate the CD133 status. Non-parametric statistics, univariate and multivariate analysis were used. Results: From October 2008 to June 2009, 46 patients with measurable mCRC had received cetuximab as salvage line, and all of them had treated with 5FU-based regimen as first line. In first line chemotherapy, the median OS was 33.1 months (95% CI, 25.6-40.4) in the CD133-positive patients as compared with 16.0 months (95% CI, 0.938-31.1) in the CD133-negative patients (P=0.004), but there were no statistically significant difference in PFS between both group. In salvage therapy with cetuximab, the median OS was 8.8 months (95% CI, 5.24-12.4) in the CD133-positive patients as compared with 5.1 months (95% CI, 3.23-6.90) in the CD133-negative patients (P=0.007). The median PFS was also significantly better in CD133-positive patients, with a median of 5.2 month (95% CI, 2.96-7.51) in the CD133-positive patients as compared with 2.8 month (95% CI, 1.48-4.06) in CD133- negative patients (P=0.046). Univariate and multivariate Cox proportional hazards regression was performed, and it is shown that CD133 predicted OS and PFS of cetuximab. Conclusions: CD133 status was correlated with the prognosis of patients

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Cytology & Histology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Cytology & Histology
  • SubjectPathology & Lab Medicine
  • BylineArticles whose byline prints “Dai Inoue”
  • BylineArticles whose byline prints “Satoshi Matsusaka”
  • BylineArticles whose byline prints “Noiriko Yamamoto”
  • BylineArticles whose byline prints “Mitsukuni Suenaga”
  • BylineArticles whose byline prints “Eiji Shinozaki”
  • BylineArticles whose byline prints “Nobuyuki Mizunuma”
  • BylineArticles whose byline prints “Yuichi Ishikawa”
  • BylineArticles whose byline prints “Kiyohiko Hatake”